AxoGen Company Profile (NASDAQ:AXGN)

About AxoGen (NASDAQ:AXGN)

AxoGen, Inc. provides surgical solutions for peripheral nerve injuries. The companys surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that is used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed. In addition, the company offers AcroVal neurosensory and motor testing system, which consists of AcroGrip for use in hand grip strength measurement; AcroPinch for measuring pinch strength; and Pressure-Specified Sensory Device, a somatosensory evaluation and measurement device. Further, it provides AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals in the United States, Canada, the United Kingdom and other European countries, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.

Industry, Sector and Symbol:

Sector: Medical
Industry: Medical Appliances & Equipment
Sub-Industry: N/A
Symbol: NASDAQ:AXGN
CUSIP: N/A
Web: www.axogeninc.com

Capitalization:

Market Cap: $648.18 million
Outstanding Shares: 33,240,000

Average Prices:

50 Day Moving Avg: $18.43
200 Day Moving Avg: $15.34
52 Week Range: $7.65 - $19.72

P/E:

Trailing P/E Ratio: N/A
Foreward P/E Ratio: -243.75
P/E Growth: 0.00

Sales & Book Value:

Annual Revenue: $50.02 million
Price / Sales: 12.96
Book Value: $0.34 per share
Price / Book: 57.35

Profitability:

EBITDA: ($8,050,000.00)
Net Margins: -27.50%
Return on Equity: -114.64%
Return on Assets: -27.71%

Debt:

Debt-to-Equity Ratio: 1.80%
Current Ratio: 3.67%
Quick Ratio: 3.09%

Misc:

Average Volume: 215,723 shs.
Beta: 0.29
Short Ratio: 5.8

Frequently Asked Questions for AxoGen (NASDAQ:AXGN)

What is AxoGen's stock symbol?

AxoGen trades on the NASDAQ under the ticker symbol "AXGN."

How were AxoGen's earnings last quarter?

AxoGen, Inc. (NASDAQ:AXGN) announced its quarterly earnings data on Wednesday, August, 2nd. The company reported ($0.06) EPS for the quarter, topping the Zacks' consensus estimate of ($0.08) by $0.02. The firm earned $15.20 million during the quarter, compared to analyst estimates of $14.40 million. AxoGen had a negative return on equity of 114.64% and a negative net margin of 27.50%. The company's revenue was up 46.2% on a year-over-year basis. During the same period last year, the company earned ($0.09) earnings per share. View AxoGen's Earnings History.

When will AxoGen make its next earnings announcement?

AxoGen is scheduled to release their next quarterly earnings announcement on Tuesday, October, 31st 2017. View Earnings Estimates for AxoGen.

Where is AxoGen's stock going? Where will AxoGen's stock price be in 2017?

6 brokerages have issued 12-month target prices for AxoGen's stock. Their predictions range from $11.00 to $23.00. On average, they anticipate AxoGen's share price to reach $17.40 in the next year. View Analyst Ratings for AxoGen.

Who are some of AxoGen's key competitors?

Some companies that are related to AxoGen include Aimmune Therapeutics (AIMT), Natus Medical Incorporated (BABY), Varex Imaging (VREX), Acorda Therapeutics (ACOR), China Cord Blood Corporation (CO), Immunomedics (IMMU), LHC Group (LHCG), Sangamo Therapeutics (SGMO), Lexicon Pharmaceuticals (LXRX), Esperion Therapeutics (ESPR), Irhythm Tech (IRTC), MyoKardia (MYOK), Dermira (DERM), Dynavax Technologies Corporation (DVAX), Accelerate Diagnostics (AXDX), Spectrum Pharmaceuticals (SPPI), Glaukos Corporation (GKOS) and OraSure Technologies (OSUR).

How do I buy AxoGen stock?

Shares of AxoGen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AxoGen's stock price today?

One share of AxoGen stock can currently be purchased for approximately $19.50.

MarketBeat Community Rating for AxoGen (NASDAQ AXGN)

Community Ranking:		3.4 out of 5 ( )
Outperform Votes:		104 (Vote Outperform)
Underperform Votes:		50 (Vote Underperform)
Total Votes:		154

MarketBeat's community ratings are surveys of what our community members think about AxoGen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Consensus Ratings for AxoGen (NASDAQ:AXGN) (How are Consensus Ratings Calculated?)

Ratings Breakdown:	6 Buy Ratings
Consensus Rating:	Buy (Score: 3.00)
Consensus Price Target:	$17.40 (10.77% downside)

Consensus Price Target History for AxoGen (NASDAQ:AXGN)

Analysts' Ratings History for AxoGen (NASDAQ:AXGN)

Show:

Date	Firm	Action	Rating	Price Target	Impact on Share Price
9/30/2017	Leerink Swann	Reiterated Rating	Outperform	$22.00 -> $23.00	Medium
9/12/2017	Roth Capital	Reiterated Rating	Buy	$18.00 -> $21.00	Low
8/21/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$18.00	Low
5/19/2017	Wedbush	Reiterated Rating	Outperform	$17.00 -> $14.00	High
11/22/2016	JMP Securities	Reiterated Rating	Buy		N/A
11/22/2016	Lake Street Capital	Upgrade	Hold -> Buy	$9.00 -> $11.00	N/A

(Data available from 10/18/2015 forward)

Earnings History for AxoGen (NASDAQ:AXGN)

Earnings by Quarter for AxoGen (NASDAQ:AXGN)

Earnings History by Quarter for AxoGen (NASDAQ AXGN)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
10/31/2017		($0.06)					N/A
8/2/2017	Q2 2017	($0.08)	($0.06)	$14.40 million	$15.20 million	View	Listen
5/4/2017	Q1 2017	($0.10)	($0.11)	$11.83 million	$12.24 million	View	Listen
2/22/2017	Q4 2016	($0.09)	($0.10)		$11.41 million	View	Listen
11/2/2016	Q3 2016	($0.08)	($0.08)	$11.21 million	$11.21 million	View	N/A
8/3/2016	Q2	($0.12)	($0.09)	$9.28 million	$10.38 million	View	N/A
11/5/2015	Q3 2015	($0.12)	($0.11)	$6.70 million	$8.15 million	View	N/A
8/6/2015	Q2 2015	($0.15)	($0.13)	$5.89 million	$6.42 million	View	N/A
5/5/2015	Q1 2015	($0.17)	($0.16)	$4.90 million	$4.95 million	View	N/A
11/13/2014	Q3 2014	($0.24)	($0.19)		$4.67 million	View	N/A
8/4/2014	Q2 2014	($0.22)	($0.21)	$3.30 million	$4.21 million	View	N/A
4/30/2014	Q1 2014	($0.26)	($0.24)	$2.75 million	$3.14 million	View	N/A
3/6/2014		($0.22)	($0.24)			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for AxoGen (NASDAQ:AXGN)

2017 EPS Consensus Estimate: ($0.29)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2017	3	($0.12)	($0.07)	($0.10)
Q2 2017	3	($0.06)	($0.04)	($0.05)
Q3 2017	4	($0.10)	($0.03)	($0.06)
Q4 2017	3	($0.14)	($0.04)	($0.08)
Q1 2018	2	($0.10)	$0.01	($0.05)
Q2 2018	2	($0.05)	$0.03	($0.01)
Q3 2018	1	$0.04	$0.04	$0.04

(Data provided by Zacks Investment Research)

Dividend History for AxoGen (NASDAQ:AXGN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading and Institutional Ownership History for AxoGen (NASDAQ:AXGN)

Insider Ownership Percentage: 9.33%
Institutional Ownership Percentage: 66.47%

Institutional Ownership by Quarter for AxoGen (NASDAQ:AXGN)

Insider Trades by Quarter for AxoGen (NASDAQ:AXGN)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
9/11/2017	Robert James Rudelius	Director	Sell	16,143	$18.00	$290,574.00
10/7/2016	Amy Mcbride Wendell	Director	Buy	13,333	$7.50	$99,997.50
10/7/2016	John P Engels	VP	Buy	4,000	$7.50	$30,000.00
10/7/2016	Karen L Zaderej	CEO	Buy	10,000	$7.50	$75,000.00
10/7/2016	Peter J Mariani	CFO	Buy	3,333	$7.50	$24,997.50
8/9/2016	Joseph M Mandato	Director	Sell	149,618	$8.54	$1,277,737.72
8/8/2016	Joseph M Mandato	Director	Sell	107,450	$8.63	$927,293.50
7/21/2016	James E Flynn	Insider	Sell	102,136	$6.70	$684,311.20
7/18/2016	James E Flynn	Insider	Sell	279,303	$7.53	$2,103,151.59
9/18/2015	James E Flynn	Insider	Sell	345,000	$5.50	$1,897,500.00
6/3/2015	Joseph M Mandato	Director	Buy	6,500	$3.10	$20,150.00
6/2/2015	Lee Robert Johnston Jr	Insider	Buy	5,000	$3.06	$15,300.00
4/8/2015	James E Flynn	Insider	Sell	144,385	$3.25	$469,251.25
12/10/2014	Lee Robert Johnston Jr	CFO	Buy	10,000	$3.06	$30,600.00
8/12/2014	Mark Stephen Gold	Director	Buy	20,000	$2.29	$45,800.00
8/8/2014	Mark Stephen Gold	Director	Buy	11,000	$2.31	$25,410.00
6/6/2014	Lee Robert Johnston Jr	CFO	Buy	10,000	$2.58	$25,800.00
6/3/2014	Gregory Gene Freitag	CFO	Buy	5,200	$2.45	$12,740.00
6/3/2014	Karen L Zaderej	CEO	Buy	5,000	$2.43	$12,150.00
5/20/2014	Jill F Schiaparelli	SVP	Buy	2,000	$2.63	$5,260.00
5/12/2014	Karen L Zaderej	CEO	Buy	5,000	$2.70	$13,500.00
5/7/2014	Mark Stephen Gold	Director	Buy	1,977	$2.60	$5,140.20
3/13/2014	Karen L Zaderej	CEO	Buy	1,500	$3.49	$5,235.00
8/29/2013	Shawn F Mccarrey	SVP	Buy	25,000	$3.21	$80,250.00
8/24/2013	Shawn F Mccarrey	SVP	Buy	5,000	$3.00	$15,000.00
8/14/2013	Jill F Schiaparelli	SVP	Buy	5,000	$3.00	$15,000.00
8/14/2013	John Frederick Harper	Director	Buy	66,666	$3.00	$199,998.00
8/14/2013	Karen L Zaderej	CEO	Buy	8,334	$3.00	$25,002.00
12/4/2012	Jill F Schiaparelli	SVP	Buy	2,000	$2.55	$5,100.00
11/29/2012	Jill F Schiaparelli	SVP	Buy	1,000	$2.70	$2,700.00
11/15/2012	Jill F Schiaparelli	SVP	Buy	2,750	$2.56	$7,040.00
10/1/2012	John Frederick Harper	Director	Buy	86,557	$3.61	$312,470.77

(Data available from 1/1/2013 forward)

Headline Trends for AxoGen (NASDAQ:AXGN) Latest Headlines for AxoGen (NASDAQ:AXGN)

Source:

Date	Headline
	AxoGen, Inc. to Report Third Quarter 2017 Financial Results and Host Conference Call on November 1, www.nasdaq.com - October 17 at 5:05 PM
	AxoGen, Inc. to Report Third Quarter 2017 Financial Results and Host Conference Call on November 1, 2017 finance.yahoo.com - October 17 at 5:05 PM
	ETFs with exposure to AxoGen, Inc. : October 13, 2017 finance.yahoo.com - October 13 at 4:54 PM
	Notable ETF Outflow Detected - DWAS, CORT, CBM, AXGN www.thestreet.com - October 10 at 5:35 PM
	AxoGen, Inc. (AXGN) Receives Average Rating of "Buy" from Brokerages www.americanbankingnews.com - October 8 at 6:50 AM
	AxoGen, Inc. (AXGN) Expected to Post Quarterly Sales of $15.58 Million www.americanbankingnews.com - October 6 at 4:48 AM
	-$0.08 Earnings Per Share Expected for AxoGen, Inc. (AXGN) This Quarter www.americanbankingnews.com - October 4 at 6:26 PM
	AxoGen to Participate at 99th Annual American Association of Oral and Maxillofacial Surgeons Meeting finance.yahoo.com - October 2 at 4:12 PM
	ETFs with exposure to AxoGen, Inc. : October 2, 2017 finance.yahoo.com - October 2 at 4:12 PM
	AxoGen, Inc. (AXGN) Given "Outperform" Rating at Leerink Swann www.americanbankingnews.com - September 30 at 1:38 PM
	ETFs with exposure to AxoGen, Inc. : September 22, 2017 finance.yahoo.com - September 22 at 12:56 PM
	AxoGen, Inc. (AXGN) Receives Average Recommendation of "Buy" from Brokerages www.americanbankingnews.com - September 13 at 6:38 AM
	Robert James Rudelius Sells 16,143 Shares of AxoGen, Inc. (AXGN) Stock www.americanbankingnews.com - September 12 at 7:52 PM
	AxoGen, Inc. (AXGN) Stock Rating Reaffirmed by Roth Capital www.americanbankingnews.com - September 12 at 9:30 AM
	ETFs with exposure to AxoGen, Inc. : September 12, 2017 finance.yahoo.com - September 11 at 9:51 PM
	AxoGen, Inc. to Present at the Cantor Fitzgerald Global Healthcare Conference finance.yahoo.com - September 11 at 4:49 PM
	AxoGen, Inc. :AXGN-US: Earnings Analysis: Q2, 2017 By the Numbers : September 8, 2017 finance.yahoo.com - September 8 at 9:41 PM
	AxoGen, Inc. (AXGN) Expected to Post Earnings of -$0.08 Per Share www.americanbankingnews.com - August 28 at 12:24 PM
	AxoGen to Participate at 72nd Annual American Society for Surgery of the Hand Meeting finance.yahoo.com - August 24 at 4:20 PM
	Cantor Fitzgerald Reiterates "Buy" Rating for AxoGen, Inc. (AXGN) www.americanbankingnews.com - August 21 at 8:28 PM
	AxoGen (AXGN): Key Points From Non Deal Roadshow - Cantor www.streetinsider.com - August 21 at 4:16 PM
	AxoGen, Inc. (AXGN) Given Average Recommendation of "Buy" by Analysts www.americanbankingnews.com - August 19 at 6:50 AM
	AxoGen, Inc. breached its 50 day moving average in a Bullish Manner : AXGN-US : August 15, 2017 finance.yahoo.com - August 15 at 5:12 PM
	Financial Comparison: Medtronic PLC (MDT) vs. AxoGen (AXGN) www.americanbankingnews.com - August 15 at 12:38 PM
	AxoGen, Inc. (NASDAQ:AXGN) Expected to Announce Quarterly Sales of $15.58 Million www.americanbankingnews.com - August 12 at 7:22 PM
	AxoGen, Inc. – Value Analysis (NASDAQ:AXGN) : August 11, 2017 finance.yahoo.com - August 11 at 9:45 PM
	FY2017 EPS Estimates for AxoGen, Inc. Raised by Cantor Fitzgerald (NASDAQ:AXGN) www.americanbankingnews.com - August 10 at 1:50 PM
	Analysts Expect AxoGen, Inc. (NASDAQ:AXGN) Will Announce Earnings of -$0.08 Per Share www.americanbankingnews.com - August 10 at 8:06 AM
	Q3 2017 Earnings Estimate for AxoGen, Inc. Issued By Wedbush (AXGN) www.americanbankingnews.com - August 7 at 8:09 AM
	Q3 2017 EPS Estimates for AxoGen, Inc. (AXGN) Reduced by Analyst www.americanbankingnews.com - August 7 at 8:08 AM
	AxoGen, Inc. (AXGN) Forecasted to Post FY2019 Earnings of $0.16 Per Share www.americanbankingnews.com - August 4 at 7:40 PM
	Edited Transcript of AXGN earnings conference call or presentation 2-Aug-17 8:30pm GMT finance.yahoo.com - August 3 at 5:41 PM
	AxoGen, Inc. (AXGN) Releases Earnings Results, Beats Expectations By $0.02 EPS www.americanbankingnews.com - August 3 at 3:38 PM
	AxoGen reports 2Q loss finance.yahoo.com - August 2 at 10:02 PM
	AxoGen, Inc. Reports 2017 Second Quarter Financial Results finance.yahoo.com - August 2 at 5:00 PM
	AxoGen, Inc. to Present at the Wedbush PacGrow Healthcare Conference finance.yahoo.com - July 31 at 4:21 PM
	Comparing Medtronic PLC (MDT) & AxoGen (AXGN) www.americanbankingnews.com - July 29 at 2:09 PM
	AxoGen, Inc. breached its 50 day moving average in a Bearish Manner : AXGN-US : July 28, 2017 finance.yahoo.com - July 28 at 5:38 PM
	AxoGen (AXGN) versus Integer Holdings (ITGR) Head to Head Survey www.americanbankingnews.com - July 27 at 6:38 PM
	AxoGen, Inc. (AXGN) Set to Announce Quarterly Earnings on Wednesday www.americanbankingnews.com - July 26 at 7:56 AM
	AxoGen, Inc. (NASDAQ:AXGN) Given Average Rating of "Buy" by Brokerages www.americanbankingnews.com - July 25 at 8:24 AM
	Analysts Anticipate AxoGen, Inc. (NASDAQ:AXGN) to Post -$0.08 EPS www.americanbankingnews.com - July 20 at 10:18 PM
	AxoGen, Inc. Discloses Terms of Recent Equity Award finance.yahoo.com - July 20 at 5:44 PM
	Globus Medical (GMED) & AxoGen (NASDAQ:AXGN) Critical Review www.americanbankingnews.com - July 20 at 5:21 PM
	AxoGen, Inc. to Report Second Quarter 2017 Financial Results and Host Conference Call on Wednesday, www.nasdaq.com - July 19 at 5:29 PM
	AxoGen, Inc. to Report Second Quarter 2017 Financial Results and Host Conference Call on Wednesday, August 2, 2017 finance.yahoo.com - July 19 at 5:29 PM
	Integer Holdings (ITGR) & AxoGen (NASDAQ:AXGN) Head to Head Analysis www.americanbankingnews.com - July 16 at 12:26 PM
	Comparing Sunshine Heart (SSH) & AxoGen (NASDAQ:AXGN) www.americanbankingnews.com - July 16 at 12:28 AM
	Reviewing Sunshine Heart (SSH) and AxoGen (NASDAQ:AXGN) www.americanbankingnews.com - July 15 at 10:04 PM
	Reviewing Globus Medical (GMED) and AxoGen (NASDAQ:AXGN) www.americanbankingnews.com - July 15 at 8:07 AM